Down 12% from Oct 28 to Nov 10.
“The decrease of $0.2 million was due primarily to a decrease in license royalty revenues”
ABUS's Quality Score fell 2 points on Tue, Nov 10, to 2. It closed away from its high of the day (3 chart checks stopped).
Follow ABUS's news. Pro members can get an alert when Arbutus Biopharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Long-term trend | −3 |
| Latest filing | 8-K, Nov 10 |
ReportThis morning: a profit of $0.30 a share. Past reports ›
In the newsForm 8K Arbutus Biopharma Corp For: 10 November By Investing.com
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
ABUS closed +0.7% that day.
Expected to report Mon Mar 22, before the open
About 15 quarters
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
ABUS is #106 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 106 |
Expected to report Mon Mar 22, before the open (in 132 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $0.30 a share, from a loss of $0.04.
“The decrease of $0.2 million was due primarily to a decrease in license royalty revenues, primarily due to a decline in Alnylam’s sales of ONPATTRO.”
ABUS's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.
No outlook figures read from this release.
“This increase was due primarily to higher employee compensation-related expenses driven by the one-time cash bonuses paid to the Company’s executives in consideration of the significant efforts and accomplishments associated with Moderna Settlement Agreement.”
From its results filing (SEC filing · Nov 10)
Its share count grew 8.3% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | -0.3% | +2.7% | not yet |
| Aug 12, 2026 | -1.7% | -1.7% | +3.6% |
| May 13, 2026 | +4.2% | 0.0% | -2.5% |
Sales grew in five of the last seven years, to $14.1M in 2025. It lost money in each of the eight years.
RSI 37.1, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ABUS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
“We face a broad range of current and potential competitors, from established global pharmaceutical companies with significant resources, to research-stage companies.”
ABUS scores 2 today, which Breakaway calls Below Average. It is #106 of 281 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 12% from Oct 28 to Nov 10. Cash lasts about 15 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ABUS scores 2 today, which Breakaway calls Below Average (0 to 5). That is #106 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ABUS's 2.
Expected to report Mon Mar 22, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ABUS closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.